The Inflation Reduction Act (IRA) was passed into law in August 2022 and is being implemented currently in the US. The moderated panel will be asked to consider how the IRA could affect the cost of medicines for patients. This discussion will focus primarily on price setting, price inflation penalties, and out-of-pocket spending caps relating to the Act, considering: 1) impact on clinical development both pre and post market; 2) effect on generic and biosimilar entry; 3) implications for launch prices, price trajectory after launch, willingness to discount, and competitor response 4) impact on market outside of Medicare, such as uninsured or private insurance.
Kirsten Axelsen, Policy Advisor at Charles River Associates
Jim Greenwood, Chair, Life Sciences Policy Practice at DLA Piper
Rhett Johnson, Vice President, Life Sciences at Charles River Associates
Darius Lakdawalla, Quintiles Chair in Pharmaceutical Development and Regulatory Innovation at University of Southern California
John Stanford, Executive Director at Incubate
Greg Bell, Vice President and Practice Leader, Life Sciences at Charles River Associates
To submit your registration for review, click here.